Metraipolis › archive › dc_c670ade0454d
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without… — Europe PMC PMID:41360639
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41360639
- DOI
- 10.1002/cam4.71220
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T03:06:27.004Z
- SHA-256 of the archived text
ba3ad91f5064d0b54bcd88a93a9a04a2fff1e4f75910f388de58b4786fc4e318- Stable URL of this page
https://metraipolis.com/documento/dc_c670ade0454d
How to cite
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without… — Europe PMC PMID:41360639 — Europe PMC (en), https://europepmc.org/article/MED/41360639 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c670ade0454d (Metraipolis archive dc_c670ade0454d, sha256 ba3ad91f5064d0b54bcd88a93a9a04a2fff1e4f75910f388de58b4786fc4e318)
BibTeX
@misc{dcc670ade0454d,
title = {A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without… — Europe PMC PMID:41360639},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41360639},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c670ade0454d; sha256 ba3ad91f5064d0b54bcd88a93a9a04a2fff1e4f75910f388de58b4786fc4e318},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41360639. Agents can read the archived copy with the MCP tool read_document.